10x Genomics, Inc. — Director's Dealing 2020

Dec 24, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2020-12-22

Reporting Person: Saxonov Serge (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-10	Class A Common Stock	G	104960	$0.00	Disposed	861839	Direct
2020-12-10	Class A Common Stock	G	104960	$0.00	Acquired	104960	Indirect
2020-12-14	Class A Common Stock	G	15000	$0.00	Disposed	89960	Indirect
2020-12-14	Class A Common Stock	G	15000	$0.00	Acquired	876839	Direct
2020-12-22	Class A Common Stock	M	2667	$1.07	Acquired	879506	Direct
2020-12-22	Class A Common Stock	M	962	$1.20	Acquired	880468	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-22	Stock Option (right to buy)	$1.07	M	2667	Disposed	2026-11-18	Class A Common Stock (2667)	Direct
2020-12-22	Stock Option (right to buy)	$1.20	M	962	Disposed	2027-10-18	Class A Common Stock (962)	Direct

Footnotes

F1: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F2: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

F3: This option, originally for 300,000 shares, of which 191,102 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.